← Back to Clinical Trials
Recruiting NCT06444295

NCT06444295 Testing the Impact of Thrive App Versions on Alcohol Use and Posttraumatic Stress After Recent Sexual Assault

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06444295
Status Recruiting
Phase
Sponsor University of Washington
Condition Posttraumatic Stress Symptom
Study Type INTERVENTIONAL
Enrollment 464 participants
Start Date 2024-07-29
Primary Completion 2027-07-15

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Activity schedulingCognitive restructuringCoaching calls

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 464 participants in total. It began in 2024-07-29 with a primary completion date of 2027-07-15.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goal of this study is to find the most effective and efficient version of the THRIVE app. The THRIVE app is the first app-based preventative intervention that has been found to reduce alcohol misuse and posttraumatic stress in people who have recently experienced sexual assault. In this trial, participants are randomly assigned to receive different versions of the THRIVE app to compare their impact. The THRIVE app is currently only available to participants in this study.

Eligibility Criteria

Inclusion Criteria: * Have reached the legal age of majority in their current state of residence * Be able to read and speak English fluently * Own a smartphone that cannot be accessed by others while the study app is installed, or they agree to take steps to reduce the risk that someone else will access the study app * Be an enrolled undergraduate or graduate student at a recruitment site at the time of screening, or if they are on summer break, plan to be enrolled in the upcoming fall term * Reside in the same state as the recruitment site for most of the year * Have experienced a sexual assault (i.e., unwanted and non-consensual attempted/completed sexual contact) within the past 12 weeks at the time of screening * Report ≥1 past-month heavy drinking episode (i.e., 5+ drinks on a given day or 15+ drinks in a given week for participants assigned male at birth and 4+ drinks on a given day or 8+ drinks in a given week for participants assigned female or intersex at birth) at the time of screening * Endorse elevated posttraumatic stress symptoms at screening (defined as a score above a pre-established cut point on a screening measure of PTSD). Exclusion Criteria: * Active psychosis * Location outside of the US at the time of screening

Contact & Investigator

Central Contact

Emily Dworkin, PhD

✉ edworkin@uw.edu

📞 206-503-3287

Principal Investigator

Emily Dworkin, PhD

PRINCIPAL INVESTIGATOR

University of Washington

Frequently Asked Questions

Who can join the NCT06444295 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Posttraumatic Stress Symptom. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06444295 currently recruiting?

Yes, NCT06444295 is actively recruiting participants. Contact the research team at edworkin@uw.edu for enrollment information.

Where is the NCT06444295 trial being conducted?

This trial is being conducted at Seattle, United States.

Who is sponsoring the NCT06444295 clinical trial?

NCT06444295 is sponsored by University of Washington. The principal investigator is Emily Dworkin, PhD at University of Washington. The trial plans to enroll 464 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology